Induction of apoptosis and sensitization of head and neck squamous carcinoma cells to cisplatin by targeting survivin gene expression

Current Gene Therapy

Volumn 12, Issue 6, 2012, Pages 444-453

  Khan, Zakir ^a,b,c   Tiwari, Ram P ^d   Khan, Noor ^e   Prasad, Godavarthi B K S ^a   Bisen, Prakash S ^a,c,f  

^a JIWAJI UNIVERSITY   (India)

^b UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^c MADHAV INSTITUTE OF TECHNOLOGY AND SCIENCE   (India)

^d RFCL Limited   (India)

^e CSIR NATIONAL BOTANICAL RESEARCH INSTITUTE   (India)

^f DEFENCE RESEARCH AND DEVELOPMENT ESTABLISHMENT   (India)

Author keywords

Cisplatin; Head and neck squamous cell carcinoma; Lentivirus siRNA therapy; Survivin

Indexed keywords

CASPASE 3; CISPLATIN; LENTIVIRUS VECTOR; SMALL INTERFERING RNA; SURVIVIN;

APOPTOSIS; ARTICLE; CANCER GROWTH; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG SENSITIZATION; FLOW CYTOMETRY; GENE EXPRESSION; GENE SILENCING; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; NICK END LABELING; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RESTRICTION MAPPING; VIRAL GENE THERAPY; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HEAD AND NECK NEOPLASMS; HUMANS; IN SITU NICK-END LABELING; INHIBITOR OF APOPTOSIS PROTEINS; LENTIVIRUS; RNA, SMALL INTERFERING;

LENTIVIRUS;

EID: 84870158466     PISSN: 15665232     EISSN: 18755631     Source Type: Journal    
DOI: 10.2174/156652312803519805     Document Type: Article

References (57)

1. Li F, Ambrosini G, Chu EY, et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998; 396: 580-3.
2. Deveraux QL, Reed JC. IAP family proteins-suppressor of apoptosis. Genes Dev 1999; 13: 1253-62.
3. Khan Z, Bhadouria P, Gupta R, et al. Tumor control by manipulation of the human anti-apoptotic survivin gene. Curr Canc Ther Rev 2006; 2: 73-9.
4. Sah NK, Khan Z, Khan GJ, et al. Structural, functional and therapeutic biology of survivin. Cancer Lett 2006; 244: 164-71.
5. Ambrosini G, Adida C, Altieri DC. A noble anti-apoptotic gene, survivin, is expressed in cancer and lymphoma. Nat Med 1997; 3: 917-21.
6. Zaffaroni N, Pennati M, Collel G, et al. Expression of antiapoptotic gene survivin correlates with taxol resistance in human ovarian cancer. Cell Mol Life Sci 2002; 59: 1406-12.
7. Li F. Survivin study: what is the next wave? J Cell Physiol 2003; 197: 8-29.
8. Khan Z, Tiwari RP, Mulherkar R, et al. Detection of survivin and p53 in human oral cancer: correlation with clinicopathological findings. Head Neck 2009; 31: 1039-48.
9. Khan Z, Khan N, Varma AK, et al. Oxaliplatin-mediated Inhibition of Survivin Increases Sensitivity of Head and Neck Squamous Cell Carcinoma Cell Lines to Paclitaxel. Curr Cancer Drug Targets 2010; 10: 660-9.
10. Khan Z, Khan N, Tiwari RP, et al. Down-regulation of survivin by oxaliplatin diminishes radioresistance of head and neck squamous carcinoma cells. Radiother Oncol 2010; 96: 267-73.
11. O'Connor DS, Grossman D, Plescia J, et al. Regulation of apoptosis at cell division by p34(cdc2) phosphorylation of survivin. Proc Natl Acad Sci USA 2000; 97: 13103-7.
12. Olie RA, Simoes-Wust AP, Baumann B, et al. A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy, Cancer Res 2000; 60: 2805-9.
13. Li F, Ackermann EJ, Bennett CF, et al. Pleiotropic cell-division defects and apoptosis induced by interference with survivin function. Nat Cell Biol 1999; 1: 461-6.
14. Chen J, Wu W, Tahir SK, et al. Down-regulation of survivin by antisense oligonucleotides increases apoptosis, inhibits cytokinesis and anchorage-independent growth. Neoplasia 2000; 2: 235-41.
15. Altieri DC. The molecular basis and potential role of survivin in cancer diagnosis and therapy. Trends Mol Med 2001; 12: 542-7.
16. Taran J, Master Z, Yu JI, Rak J, Dumont DJ, Kerbel RS. A role of survivin in chemoresistance of endothelial cells mediated by VEGF. Proc Natl Acad Sci USA 2002; 99: 4345-9.
17. Rodel C, Hass J, Groth A, et al. Spontaneous and radiation induced apoptosis in colorectal carcinoma cells with different intrinsic radiosensitivities: survivin as a radioresistance factor. Int J Radiat Oncol Biol Phys 2003; 55: 1341-7.
18. Dobrossy L. Epidemiology of head and neck cancer: magnitude of the problem. Cancer Metastasis Rev 2005; 24: 9-17.
19. Saltz L, Kelsen D. A phase I trial of cisplatin in hypertonic saline and escalating doses of 5-fluorouracil by continuous intravenous infusion in patients with advanced malignancies. Cancer 1990; 66: 1688-91.
20. Esaki T, Nakano S, Tatsumoto T, et al. Inhibition by 5-fluorouracil of cisdiamminedichloroplatinum(II)-induced DNA interstrand cross-link removal in a HST-1 human squamous carcinoma cell line. Cancer Res 1992; 52: 6501-6.
21. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 2007; 7: 573-84.
22. Yamamoto K, Kohama G, Sunakawa H, et al. Mode of invasion, bleomycin sensitivity, and clinical course in squamous cell carcinoma of the oral cavity. Cancer 1983; 51: 2175-80.
23. Hsu S, Singh B, Schuster G. Induction of apoptosis in oral cancer cells: agents and mechanisms for potential therapy and prevention. Oral Oncol 2004; 40: 461-73.
24. Gu Y, Fan S, Xiong Y, et al. Cloning and functional characterization of TCRP1, a novel gene mediating resistance to cisplatin in an oral squamous cell carcinoma cell line. FEBS Lett 2011; 585: 881-7.
25. Zorat PL, Paccagnella A, Cavaniglial G, et al. Randomized phase III trial of neoadjuvant chemotherapy in head and neck cancer: 10-year follow-up. J Natl Cancer Inst 2004; 96: 1714-7.
26. Urba SG, Moon J, Giri PGS, et al. Organ preservation for advanced resectable cancer of the base of tongue and hypopharynx: a Southwest Oncology Group Trial. J Clin Oncol 2005; 23: 88-95.
27. Fanucchi M, Khuri FR. Chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck. Semin Oncol 2004; 31: 809-15.
28. Hsu DS, Lan HY, Huang CH, et al. Regulation of Excision Repair Cross-Complementation Group 1 by Snail Contributes to Cisplatin Resistance in Head and Neck Cancer. Clin Cancer Res 2010; 16: 4561-71.
29. Shen D, Pastan I, Gottesman MM, et al. Crossresistance to methotrexate and metals in human cisplatin-resistant cell lines results from a pleiotropic defect in accumulation of these compounds associated with reduced plasma membrane binding proteins. Cancer Res 1998; 58: 268-75.
30. Bauer JA, Kumar B, Cordell KG, et al. Targeting apoptosis to overcome cisplatin resistance: a translational study in head and neck cancer. Int J Radiat Oncol Biol Phys 2007; 69: 106-8.
31. Gu F, Ma Y, Zhang Z, et al. Expression of Stat3 and Notch1 is associated with cisplatin resistance in head and neck squamous cell carcinoma. Oncol Rep 2010; 23: 671-6.
32. Yamano Y, Uzawa K, Saito K, et al. Identification of cisplatinresistance related genes in head and neck squamous cell carcinoma. Int J Cancer 2010; 126: 437-49.
33. Dai Z, Huang Y, Sadee W, et al. Growth factor signaling and resistance to cancer chemotherapy. Curr Top Med Chem 2004; 4: 1347-56.
34. Magne N, Fischel J-L, Tiffon C, et al. Molecular mechanisms underlying the interaction between ZD1839 ('Iressa') and cisplatin/5-fluorouracil. Br J Cancer 2003; 89: 585-92.
35. Simons AL, Ahmad IM, Mattson DM, et al. 2-Deoxy-d-Glucose Combined with Cisplatin Enhances Cytotoxicity via Metabolic Oxidative Stress in Human Head and Neck Cancer Cells. Cancer Res 2007; 67: 3364-70.
36. Qin XF, An DS, Chen ISY, et al. Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5. Proc Natl Acad Sci USA 2003; 100: 183-8.
37. Bandyopadhyay B, Fan J, Guan S, et al. A "traffic control" role for TGFbeta3: orchestrating dermal and epidermal cell motility during wound healing. J Cell Biol 2006; 172: 1093-105.
38. Guan S, Chen M, Woodley DT, et al. Nck adapter controls neuritogenesis by maintaining cellular paxillin level. Mol Cell Biol 2007; 17: 6001-11.
39. Kahl CA, Marsh J, Fyffe J, et al. Human Immunodeficiency Virus Type 1-Derived Lentivirus Vectors Pseudotyped with Envelope Glycoproteins Derived from Ross River Virus and Semliki Forest Virus. J Virol 2004; 78: 1421-30.
40. Kremer M, Suezer Y, Martinez-Fernandez Y, et al. Vaccinia virus replication is not affected by APOBEC3 family members. Viro J 2006; 3: 86.
41. Gelmini S, Orlando C, Sestini R, et al. Quantitative polymerase chain reactionbased homogeneous assay with fluorogenic probes to measure c-erbB-2 oncogene amplification. Clin Chem 1997; 43: 752-8.
42. Singer O, Verma IM. Applications of lentiviral vectors for shRNA delivery and transgenesis Curr Gene Ther 2008; 8: 483-8.
43. Kumar P, Woon-Khiong C. Optimization of Lentiviral Vectors Generation for Biomedical and Clinical Research Purposes: Contemporary Trends in Technology Development and Applications. Curr Gene Ther 2011; 11: 144-53.
44. Baker M. Gene-editing nucleases. Nat Methods 2012; 9: 23-6.
45. Handel E-M, Cathomen T. Zinc-Finger Nuclease Based Genome Surgery: It's All About Specificity. Curr Gene Ther 2011; 11: 28-37.
46. de Souza N. Primer: Genome editing with engineered nucleases. Nat Methods 2012; 9: 27.
47. Lens SMA, Wolthuis RMF, Klompmaker R, et al. Survivin is required for a sustained spindle checkpoint arrest in response to lack of tension. EMBO J 2003; 22: 2934-47.
48. Williams NS, Gaynor RB, Scoggin S, et al. Identification and validation of genes involved in the pathogenesis of colorectal cancer using cDNA microarrays and RNA interference. Clin Cancer Res 2003; 9: 931-46.
49. Kappler M, Bache M, Bartel F, et al. Knockdown of survivin expression by small interfering RNA reduces the clonogenic survival of human sarcoma cell lines independently of p53. Cancer Gene Ther 2004; 11: 186-93.
50. Miao GY, Lu Q-M, Zhang X-L. Downregulation of survivin by RNAi inhibits growth of human gastric carcinoma cells. World J Gastroenterol 2007; 13: 1170-4.
51. Tsuji N, Asanuma K, Kobayashi D, et al. Introduction of a Survivin Gene-specific Small Inhibitory RNA Inhibits Growth of Pancreatic Cancer Cells. Anticancer Res 2005; 25: 3967-72.
52. Sunderman FW Jr, Sporn J, Hopfer SM, et al. Platinum in blood mononuclear cells from patients after cisplatin therapy. Ann Clin Lab Sci 1990; 20: 379-84.
53. Magne N, Fischel JL, Dubreuil A, et al. Sequence-dependent effects of ZD1839 ('Iressa') in combination with cytotoxic treatment in human head and neck cancer. Br J Cancer 2002; 86: 819-27.
54. Tavassoli M, Soltaninia J, Rudnicka J, et al. Tamoxifen inhibits the growth of head and neck cancer cells and sensitizes these cells to cisplatin induced-apoptosis: role of TGF-β1. Carcinogenesis 2002; 23:1569-75.
55. Ikeguchi M, Tatebe S, Kaibara N, et al. Changes in levels of expression of p53 and the product of the bcl-2 in lines of gastric cancer cells during cisplatin-induced apoptosis. Eur Surg Res 1997; 29: 396-402.
56. Kolfschoten GM, Hulscher TM, Schrier SM, et al. Time-dependent changes in factors involved in the apoptotic process in human ovarian cancer cells as a response to cisplatin. Gynecol Oncol 2002; 84: 404-12.
57. Tamm I, Wang Y, Sausville E, et al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 1998; 58: 5315-20.